$CEMI - Chembio Diagnostics

Set up for a major short squeeze.

Trading below cash on hand. 30% of book value.

Market Cap: $11M. Cash Position On 9/30: $20.5M

Granted extension until 4/15/2023 to gain compliance.

✅ $3.25M C.D.C. Contract To Develop Syphilis Test

✅ Dual Covid/Flu Test

✅ Only F.D.A. Approved Dual HIV-SYPHILIS Test       H.I.V. testing is a $4 billion market.

✅  Developing Monkey POX Test With N.I.H. Guidance.

Potential takeover target at in the $3 range. Potential suitors are $AMZN $DGX $AZN $TAK $JNJ

There are any number of reasonably expected catalysts that could triple the share price at anytime.

When Chembio announced a $23.5M order from Brazil for its Covid test it traded over 600,000,000 shares in two days and the share price tripled.

Covid is surging in Brazil. Don't be short when a new order is announced.

When Chembio received a $3.23M order from the C.D.C. on 9/1 to develop a rapid test to detect Syphilis the share price tripled.

When Chembio receives a C.L.I.A. waiver for its dual HIV-SYPHILIS test which allows it to be sold to 250K C.L.I.A. labs the share price triples.

Buy a few shares under .50.

Current share price is an early Christmas gift.

🎄🎅🎁🎄🎅🎁🎄🎅🎁🎄🎅🎁🎄🎅🎁🎄🎅🎁🎄🎅🎁